Beckman Coulter Completes Olympus Dx Buy | GenomeWeb

NEW YORK (GenomeWeb News) – Beckman Coulter has completed its $780 million acquisition of Olympus' lab-based diagnostics business, the firm announced over the weekend.

Beckman funded the acquisition with $495 million that was raised through the issuance of two, $250 million senior note offerings, and around $240 million from a common stock offering of approximately 4.7 million shares issued to the public at a price of $53 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new single-cell RNA sequencing technique to study proliferating cells, and more.

South African researchers uncover bone cancer in an ancient hominin ancestor.

English bulldogs suffer from low genetic diversity and might have to be outbred to improve their health, according to a new study.

Theresa May tries to reassure researchers about the UK's commitment to science, New Scientist reports.